These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 9498726)
61. Sertindole in schizophrenia: efficacy and safety issues. Muscatello MR; Bruno A; Micali Bellinghieri P; Pandolfo G; Zoccali RA Expert Opin Pharmacother; 2014 Sep; 15(13):1943-53. PubMed ID: 25084209 [TBL] [Abstract][Full Text] [Related]
62. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers. Mahatthanatrakul W; Sriwiriyajan S; Ridtitid W; Boonleang J; Wongnawa M; Rujimamahasan N; Pipatrattanaseree W J Clin Pharm Ther; 2012 Apr; 37(2):221-5. PubMed ID: 21518375 [TBL] [Abstract][Full Text] [Related]
63. Selegiline transdermal system: an examination of the potential for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medications. Azzaro AJ; Ziemniak J; Kemper E; Campbell BJ; VanDenBerg C J Clin Pharmacol; 2007 Feb; 47(2):146-58. PubMed ID: 17244765 [TBL] [Abstract][Full Text] [Related]
64. In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole--a 123I IBZM single photon emission tomography (SPET) study. Pilowsky LS; O'Connell P; Davies N; Busatto GF; Costa DC; Murray RM; Ell PJ; Kerwin RW Psychopharmacology (Berl); 1997 Mar; 130(2):152-8. PubMed ID: 9106913 [TBL] [Abstract][Full Text] [Related]
65. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. Chen C; Bujanover S; Kareht S; Rapoport AM Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369 [TBL] [Abstract][Full Text] [Related]
66. Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. Teng R; Kujacic M; Hsia J Clin Ther; 2014 Sep; 36(9):1217-25. PubMed ID: 25069798 [TBL] [Abstract][Full Text] [Related]
67. Alprazolam pharmacokinetics in women on low-dose oral contraceptives. Scavone JM; Greenblatt DJ; Locniskar A; Shader RI J Clin Pharmacol; 1988 May; 28(5):454-7. PubMed ID: 3392243 [TBL] [Abstract][Full Text] [Related]
69. Disposition of alprazolam in human volunteers. Differences between genders. Kristjánsson F; Thorsteinsson SB Acta Pharm Nord; 1991; 3(4):249-50. PubMed ID: 1781916 [TBL] [Abstract][Full Text] [Related]
70. The effects of sertindole on sensory gating, sensorimotor gating, and cognition in healthy volunteers. Holstein DH; Csomor PA; Geyer MA; Huber T; Brugger N; Studerus E; Vollenweider FX J Psychopharmacol; 2011 Dec; 25(12):1600-13. PubMed ID: 21890590 [TBL] [Abstract][Full Text] [Related]
71. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects. Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235 [TBL] [Abstract][Full Text] [Related]
72. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. Rampe D; Murawsky MK; Grau J; Lewis EW J Pharmacol Exp Ther; 1998 Aug; 286(2):788-93. PubMed ID: 9694935 [TBL] [Abstract][Full Text] [Related]
73. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119 [TBL] [Abstract][Full Text] [Related]
74. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. Aweeka F; Jayesekara D; Horton M; Swan S; Lambrecht L; Wilner KD; Sherwood J; Anziano RJ; Smolarek TA; Turncliff RZ Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):27S-33S. PubMed ID: 10771451 [TBL] [Abstract][Full Text] [Related]
75. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505 [TBL] [Abstract][Full Text] [Related]
76. Effects of olanzapine, sertindole and clozapine on MK-801 induced visual memory deficits in mice. Mutlu O; Ulak G; Celikyurt IK; Akar FY; Erden F; Tanyeri P Pharmacol Biochem Behav; 2011 Oct; 99(4):557-65. PubMed ID: 21693127 [TBL] [Abstract][Full Text] [Related]
77. Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. Abernethy DR; Greenblatt DJ; Divoll M; Moschitto LJ; Harmatz JS; Shader RI Psychopharmacology (Berl); 1983; 80(3):275-8. PubMed ID: 6137021 [TBL] [Abstract][Full Text] [Related]
78. Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D2 receptor occupancy and behavioural conditioned avoidance response. Bundgaard C; Larsen F; Kreilgaard M; Brennum LT; Olsen CK Biopharm Drug Dispos; 2009 May; 30(4):209-20. PubMed ID: 19475539 [TBL] [Abstract][Full Text] [Related]
79. Sertindole, a potent antagonist at dopamine D₂ receptors, induces autophagy by increasing reactive oxygen species in SH-SY5Y neuroblastoma cells. Shin JH; Park SJ; Kim ES; Jo YK; Hong J; Cho DH Biol Pharm Bull; 2012; 35(7):1069-75. PubMed ID: 22791154 [TBL] [Abstract][Full Text] [Related]
80. Electrophysiological safety of sertindole in dogs with normal and remodeled hearts. Thomsen MB; Volders PG; Stengl M; Spätjens RL; Beekman JD; Bischoff U; Kall MA; Frederiksen K; Matz J; Vos MA J Pharmacol Exp Ther; 2003 Nov; 307(2):776-84. PubMed ID: 12966159 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]